Irinotecan clinical trials
Also written CPT-11, Camptosar, Campto and U-101440E.
Includes 79 studies of Irinotecan sucrosofate, 2 studies of Liposomal SN-38 and 1 study of Pegylated Liposomal Irinotecan.
Counted the way a researcher would: Irinotecan with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Irinotecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Irinotecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Jun 1996 · CAMPTOSAR · NDA 020571 (FDA, Drugs@FDA)
- European Union
- 14 Oct 2016 · Onivyde pegylated liposomal (previously Onivyde) · EMEA/H/C/004125 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
In one entry with another drug
Given together, or one or the other
Studies by the year they started
781 studies that test it; most in 2003 (45)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 3 |
| 1997 | 10 |
| 1998 | 22 |
| 1999 | 25 |
| 2000 | 25 |
| 2001 | 31 |
| 2002 | 31 |
| 2003 | 45 |
| 2004 | 39 |
| 2005 | 31 |
| 2006 | 41 |
| 2007 | 29 |
| 2008 | 30 |
| 2009 | 30 |
| 2010 | 16 |
| 2011 | 20 |
| 2012 | 20 |
| 2013 | 23 |
| 2014 | 23 |
| 2015 | 22 |
| 2016 | 15 |
| 2017 | 22 |
| 2018 | 24 |
| 2019 | 28 |
| 2020 | 26 |
| 2021 | 26 |
| 2022 | 24 |
| 2023 | 11 |
| 2024 | 45 |
| 2025 | 21 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 90 · Other 696
National Cancer Institute (NCI) (34) · Alliance for Clinical Trials in Oncology (28) · Memorial Sloan Kettering Cancer Center (26) · M.D. Anderson Cancer Center (15) · Children's Oncology Group (14) · Roswell Park Cancer Institute (14) · Sun Yat-sen University (13) · Pfizer (12)
Often tested with
Tested in the same studies.
Fluorouracil (144) · Oxaliplatin (126) · Leucovorin (84) · Bevacizumab (82) · Cisplatin (67) · Temozolomide (64) · Capecitabine (64) · Cetuximab (55)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 29 phase 3 studies under way
Irinotecan is the comparator. A study of two new drugs counts under both.
- 2Sacituzumab tirumotecan · Merck Sharp & Dohme LLC · next primary completion Jun 2028
- 2Tambotatug pelitecan · MediLink Therapeutics (Suzhou) Co., Ltd. · next primary completion Apr 2028
- 1Ipilimumab · Bristol-Myers Squibb
- 1Nivolumab · Bristol-Myers Squibb
- 1Daraxonrasib · Revolution Medicines, Inc.
- 1Pembrolizumab · Merck Sharp & Dohme LLC · next primary completion Sep 2028
- 1Tecotabart vedotin · LaNova Medicines Zhejiang Co., Ltd. · next primary completion Nov 2026
- 1Risvutatug rezetecan · Hansoh BioMedical R&D Company · next primary completion Dec 2030
Reaching primary completion within a year · 41, 6 in phase 3
Studies that test Irinotecan, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Nov 2026Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCCPhase 3 · Rui-hua Xu, MD, PhD
- Dec 2026Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaPhase 3 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Dec 2026Paediatric Hepatic International Tumour TrialPhase 3 · University of Birmingham
- Dec 2026A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRCPhase 3 · Sun Yat-sen University
- Jan 2027Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic CancerPhase 3 · Erasmus Medical Center
- Nov 2026Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTCPhase 2 · Sir Run Run Shaw Hospital
- Nov 2026Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.Phase 2 · Lund University Hospital
- Dec 2026NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabPhase 1/2 · Nationwide Children's Hospital
- Dec 2026Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified ChemotherapyPhase 2 · St. Jude Children's Research Hospital
Studies
Open first, then newest update. How each study uses Irinotecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 786
- Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk DiseaseRecruitingPhase 2St. Jude Children's Research HospitalNCT06023641Written as Liposomal irinotecanHow we know
- Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaRecruitingPhase 2Giselle ShollerNCT07932808Written as Naxitamab and GM-CSF in combination with irinotecan and temozolomideHow we know
- Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPSRecruitingPhase 2Italian Sarcoma GroupNCT07328425Written as IrinotecanHow we know
- Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid MalignanciesNot yet recruitingPhase 1National Health Research Institutes, TaiwanNCT07782346Written as Liposomal Irinotecan Plus CisplatinHow we know
- SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC TrialRecruitingPhase 2Northwestern UniversityNCT07748611Written as IrinotecanHow we know
- Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II StudyRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07896681Written as IrinotecanHow we know
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingPhase 2SWOG Cancer Research NetworkNCT04205968Written as IrinotecanHow we know
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingPhase 2Medical University of ViennaNCT01356290Written as IrinotecanHow we know
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid TumorsRecruitingPhase 1South Plains Oncology ConsortiumNCT02013336Written as MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamideHow we know
- Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Not yet recruitingPhase 1/2University Hospital, Strasbourg, FranceNCT07853105Written as Dinutuximab beta, Sirolimus and IrinotecanHow we know
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07194044Written as IrinotecanHow we know
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialRecruitingPhase 2Roswell Park Cancer InstituteNCT06821997Written as Irinotecan SucrosofateHow we know
- VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent GliomaRecruitingPhase 2Inova Health Care ServicesNCT07831369Written as IrinotecanHow we know
- Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant MelanomaNot yet recruitingPhase 1/2Yonsei UniversityNCT07817901Written as Pembrolizumab and IrinotecanHow we know
- ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"RecruitingPhase 2Gruppo Oncologico Italia MeridionaleNCT07381764Written as IrinotecanHow we know
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06528496Written as IrinotecanHow we know
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerRecruitingPhase 1City of Hope Medical CenterNCT04329494Written as IrinotecanHow we know
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)RecruitingPhase 3Children's Oncology GroupNCT06401330Written as IrinotecanHow we know
- A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWTRecruitingPhase 2Children's Oncology GroupNCT04322318Written as IrinotecanHow we know
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as IrinotecanHow we know
See all 786 studies that test Irinotecan →
Given beside what is tested · 433 — Irinotecan is usual care or a partner of the new treatment
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as IrinotecanHow we know
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingPhase 3GenmabNCT07775287Written as IrinotecanHow we know
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07024615Written as IrinotecanHow we know
- Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsRecruitingPhase 1/2Milton S. Hershey Medical CenterNCT06541262Written as IrinotecanHow we know
- Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05688215Written as IrinotecanHow we know
- A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07915921Written as IrinotecanHow we know
- A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line TherapyRecruitingPhase 1/2Shenzhen Majory Biotechnology Co., Ltd.NCT07235202Written as Irinotecan Liposome Injection combined with 5-FU/LVHow we know
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 3Revolution Medicines, Inc.NCT07621718Written as IrinotecanHow we know
- Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07662031Written as IrinotecanHow we know
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT TrialRecruitingPhase 3City of Hope Medical CenterNCT07271355Written as Irinotecan HydrochlorideHow we know
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingPhase 3Janssen Research & Development, LLCNCT06750094Written as IrinotecanHow we know
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06662786Written as Irinotecan HydrochlorideHow we know
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT05677490Written as IrinotecanHow we know
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07409272Written as IrinotecanHow we know
- A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic CancerNot yet recruitingPhase 1/2Daniel Nussbaum, M.D.NCT07905131Written as mFOLFIRINOX Treatment RegimenHow we know
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingPhase 3National Cancer Institute (NCI)NCT06172296Written as IrinotecanHow we know
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Artios Pharma LtdNCT04657068Written as IrinotecanHow we know
- Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaRecruitingPhase 1National Cancer Institute (NCI)NCT06995872Written as Irinotecan HydrochlorideHow we know
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as IrinotecanHow we know
- EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal CancerRecruitingPhase 1Shanghai EpimAb Biotherapeutics Co., Ltd.NCT07649655Written as IrinotecanHow we know
Showing 20 of 433.
As the comparator · 62 — what is tested is compared with Irinotecan
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerRecruitingPhase 1/2Janssen Research & Development, LLCNCT05379595Written as IrinotecanHow we know
- A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line TreatmentRecruitingPhase 3Biokin (Shanghai) Biopharmaceutical Co., Ltd.NCT07518147Written as Irinotecan hydrochlorideHow we know
- FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.RecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07790380Written as Paclitaxel, Docetaxel, IrinotecanHow we know
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingPhase 3Daiichi SankyoNCT06644781Written as Irinotecan hydrochloride (HCl)How we know
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 2/3AbbVieNCT07490301Written as IrinotecanHow we know
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT05319730Written as IrinotecanHow we know
- Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerRecruitingPhase 3Sunshine Lake Pharma Co., Ltd.NCT04415853Written as Irinotecan/TegafurHow we know
- Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.RecruitingPhase 3Gruppo Oncologico del Nord-OvestNCT06897644Written as Irinotecan (CPT-11)How we know
- A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic ChemotherapyNot yet recruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07803783Written as Liposomal irinotecanHow we know
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerRecruitingPhase 3NRG OncologyNCT06958328Written as Irinotecan HydrochlorideHow we know
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07606599Written as Irinotecan HydrochlorideHow we know
- A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07582315Written as Irinotecan HydrochlorideHow we know
- A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line TherapyRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07487896Written as IrinotecanHow we know
- A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT07621601Written as Irinotecan; Paclitaxel; DocetaxelHow we know
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07595913Written as 5-fluorouracil, Calcium folinate and IrinotecanHow we know
- SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06649292Written as Paclitaxel, Docetaxel, IrinotecanHow we know
- JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.RecruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT07284134Written as IrinotecanHow we know
- Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04342910Written as IrinotecanHow we know
- Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsNot yet recruitingPhase 3TransThera Sciences (Nanjing), Inc.NCT07328919Written as Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabineHow we know
- Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic CancerRecruitingPhase 3Fudan UniversityNCT06250972Written as Gemcitabine, Nab-paclitaxel, IrinotecanHow we know
Showing 20 of 62.
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
Results posted4
- Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaNov 4, 2026NCT04752696
- Radiosensitizing Chemotherapy withSBRT for the Treatment of Inoperable Liver and/or Lung Metastases of CRCOct 30, 2026NCT01220063
- NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary CancerOct 27, 2026NCT04005339
- FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic CancerOct 21, 2026NCT04141995
Stopped1
Newly registered2
Codes
What other systems call Irinotecan · ClinicalTrials.gg INT006650
- MeSH (NLM) D000077146IrinotecanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7673326042IRINOTECANConfirmed FDA, NLM, Wikidata
- RxNorm 51499Confirmed FDA, Wikidata
- Wikidata Q412197irinotecanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62040IrinotecanOne source FDA
- DrugBank DB00762One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077146 | Irinotecan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7673326042 | IRINOTECAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 51499 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412197 | irinotecan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62040 | Irinotecan | One source FDA |
| DrugBank | DB00762 | — | One source Wikidata |
Also registered as 7-ethyl-10-hydroxycamptothecin (UNII 0H43101T0J) and irinotecan hydrochloride (UNII 042LAQ1IIS · RxNorm 153329).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.